Teligent, Inc. (TLGTQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Teligent, Inc. (TLGTQ) trades at $0.0002 with AI Score 40/100 (Grade C). Teligent, Inc. is a specialty generic pharmaceutical company focusing on developing, manufacturing, and marketing generic topical and injectable products. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for TLGTQ: TLGTQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TLGTQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TLGTQ: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Teligent, Inc. (TLGTQ) Healthcare & Pipeline Overview
Teligent, Inc., based in Buena, New Jersey, develops and markets generic pharmaceutical products, including topicals and injectables, primarily in the United States and Canada. Currently operating under Chapter 11 bankruptcy protection, the company faces significant financial challenges within the competitive generic drug market.
What Is the Investment Thesis for TLGTQ?
Teligent, Inc. presents a high-risk investment profile due to its Chapter 11 bankruptcy filing in October 2021. The company's negative profit margin of -269.3% and gross margin of -8.2% highlight significant financial challenges. While the company continues to operate, the future value of TLGTQ stock is highly uncertain. Potential catalysts include successful reorganization and restructuring efforts, which could stabilize the company's finances and operations. However, the OTC Other tier listing and unknown disclosure status add further layers of risk. Investors should carefully consider these factors and conduct thorough due diligence before considering an investment in TLGTQ.
Based on FMP financials and quantitative analysis
TLGTQ Key Highlights
Filed for Chapter 11 bankruptcy on October 14, 2021, indicating significant financial distress.
- Operates with a negative profit margin of -269.3%, reflecting substantial losses.
- Reports a negative gross margin of -8.2%, suggesting challenges in production and sales.
- Trades on the OTC market, specifically the OTC Other tier, indicating higher risk and lower regulatory oversight.
- Employs 142 individuals, reflecting a relatively small operational scale.
Who Are TLGTQ's Competitors?
TLGTQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ZTS Zoetis Inc. | $75.44 | -1.62% | $31.6B | 85 |
| ITCI ITCI | $131.87 | +0.00% | $14.1B | 63 |
| ESALF Eisai Co., Ltd. | $29.90 | +0.00% | $8.44B | 61 |
| LNTH Lantheus Holdings, Inc. | $100.24 | -0.24% | $6.53B | 88 |
| AMRX Amneal Pharmaceuticals, Inc. | $17.90 | -1.16% | $5.72B | 65 |
| CAMRF Camurus AB (publ) | $64.00 | +0.00% | $3.81B | 63 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
| AVDL Avadel Pharmaceuticals plc | $21.64 | +0.00% | $2.12B | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TLGTQ's Key Strengths?
Specialization in topical and injectable generic drugs.
- Contract manufacturing capabilities.
- Established distribution network in the US and Canada.
- Experience in developing complex generic formulations.
What Are TLGTQ's Weaknesses?
Chapter 11 bankruptcy filing.
- Negative profit and gross margins.
- Limited financial resources.
- Dependence on a limited number of products.
What Could Drive TLGTQ Stock Higher?
Successful reorganization and restructuring efforts to emerge from Chapter 11 bankruptcy.
- Potential for new partnerships or acquisitions to strengthen the company's financial position.
- FDA approval of new generic drug products in Teligent's pipeline.
- Streamlining operations and reducing costs to improve profitability.
- Resolution of any outstanding legal or regulatory issues.
What Are the Key Risks for TLGTQ?
Uncertainty surrounding the outcome of the Chapter 11 bankruptcy proceedings.
- Inability to secure financing or restructure debt.
- Loss of key contracts or customers.
- Intense competition from larger generic drug manufacturers.
- Product liability claims or regulatory actions.
What Are the Growth Opportunities for TLGTQ?
- Expansion of Contract Manufacturing Services: Teligent can leverage its manufacturing capabilities to expand its contract manufacturing and development business. The global contract manufacturing market for pharmaceuticals is projected to reach $227.78 billion by 2028, growing at a CAGR of 6.6%. By focusing on specialized formulations and niche markets, Teligent can secure contracts with both branded and generic pharmaceutical companies, providing a stable revenue stream. Timeline: Ongoing.
- Development of Complex Generics: Focusing on the development and commercialization of complex generic drugs, such as injectables and ophthalmic solutions, can provide higher margins and less competition compared to simple generics. The complex generics market is driven by the increasing demand for affordable alternatives to branded drugs and is expected to grow significantly in the coming years. Teligent's expertise in these dosage forms can be a competitive advantage. Timeline: 2-3 years.
- Geographic Expansion into Canada: Teligent already has a presence in Canada, but expanding its product offerings and distribution network in this market can drive growth. The Canadian pharmaceutical market is relatively stable and offers opportunities for generic drug manufacturers. Focusing on specific therapeutic areas and building strong relationships with local distributors can enhance market penetration. Timeline: 1-2 years.
- Strategic Partnerships and Acquisitions: Teligent can pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. Collaborating with other pharmaceutical companies or acquiring smaller players with complementary products can create synergies and accelerate growth. This strategy can also help Teligent diversify its revenue streams and reduce its reliance on a limited number of products. Timeline: Ongoing.
- Focus on Topical Products for Dermatology: The market for topical dermatology products is growing due to the increasing prevalence of skin conditions such as psoriasis, eczema, and dermatitis. Teligent's expertise in topical formulations positions it well to capitalize on this trend. By developing and marketing innovative topical products, Teligent can capture a larger share of the dermatology market. The global dermatology market is projected to reach $36.6 billion by 2027. Timeline: 1-2 years.
What Are TLGTQ's Competitive Advantages?
- Specialized in niche generic formulations, particularly topicals and injectables.
- Established manufacturing capabilities for semi-solid and liquid products.
- Contract manufacturing relationships provide a recurring revenue stream.
- Regulatory expertise in navigating FDA approval processes for generic drugs.
What Does TLGTQ Do?
Teligent, Inc., formerly known as IGI Laboratories, Inc., was founded in 1977 and rebranded in October 2015. The company specializes in the development, manufacture, and sale of generic pharmaceutical products, including topical, injectable, complex, and ophthalmic dosage forms. Teligent serves the United States and Canadian markets, offering a range of products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. In addition to its generic product portfolio, Teligent engages in contract manufacturing and development, providing services such as the development, manufacturing, filling, and packaging of topical semi-solid and liquid products for branded and generic pharmaceutical companies, as well as over-the-counter and cosmetic markets. These topical products are used in applications ranging from cosmetics and cosmeceuticals to prescription treatments for conditions like dermatitis, psoriasis, and eczema. However, on October 14, 2021, Teligent, Inc. and its affiliates filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware, indicating significant financial distress and operational restructuring.
What Products and Services Does TLGTQ Offer?
- Develops generic pharmaceutical products.
- Manufactures generic topical products.
- Produces generic injectable products.
- Markets generic pharmaceutical products in the United States.
- Sells generic pharmaceutical products in Canada.
- Offers contract manufacturing services for topical products.
- Provides development services for pharmaceutical companies.
How Does TLGTQ Make Money?
- Develops and manufactures generic drugs to sell at a lower cost than brand-name drugs.
- Generates revenue through the sale of its generic pharmaceutical products to wholesalers, distributors, and retail pharmacies.
- Provides contract manufacturing services to other pharmaceutical companies, generating revenue from manufacturing fees.
What Industry Does TLGTQ Operate In?
Teligent operates within the specialty generic pharmaceutical industry, a sector characterized by intense competition and pricing pressures. Companies in this space focus on developing and manufacturing generic versions of branded drugs, often targeting niche markets or specialized formulations. The industry is subject to stringent regulatory oversight, particularly from the FDA, and faces ongoing challenges related to drug pricing, patent expirations, and competition from larger generic manufacturers. Teligent's bankruptcy filing underscores the financial challenges faced by smaller players in this competitive landscape, especially given the need for continuous investment in R&D and manufacturing to maintain a viable product pipeline.
Who Are TLGTQ's Key Customers?
- National chain drug stores.
- Drug wholesalers.
- Distributors.
- Group purchasing organizations.
Company Profile
Teligent, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Buena, US. TLGTQ has traded publicly since 1981.
How Teligent, Inc. Is Valued
Relative to its peer group, TLGTQ's quantitative score of 40/100 is below the peer average of 72/100.
Key Financial Metrics
Return on equity for Teligent, Inc. stands at 211.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 1.92 indicates the company holds enough short-term assets to cover its near-term obligations.
TLGTQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TLGTQ Latest News
No recent news available for TLGTQ.
TLGTQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TLGTQ.
Price Targets
Wall Street price target analysis for TLGTQ.
TLGTQ MoonshotScore
What does this score mean?
The MoonshotScore rates TLGTQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
TLGTQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing companies that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may be distressed, undergoing bankruptcy, or have limited information available to investors. Trading in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before investing in these securities.
- OTC Tier: OTC Other
- Limited financial disclosure due to the 'Unknown' disclosure status.
- High risk of delisting or trading suspension.
- Potential for fraud or manipulation due to lack of regulatory oversight.
- Significant price volatility due to low trading volume.
- Uncertainty regarding the outcome of the Chapter 11 bankruptcy proceedings.
- Verify the company's current legal status and bankruptcy proceedings.
- Review any available financial statements and disclosures.
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the potential risks and rewards of investing in TLGTQ.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal disputes involving the company.
- The company was previously listed on a major exchange (as IGI Laboratories).
- Teligent has existing manufacturing facilities and capabilities.
- The company has a history of developing and marketing generic pharmaceutical products.
- Teligent continues to operate, albeit under Chapter 11 bankruptcy protection.
- The company has a portfolio of approved generic drug products.
Common Questions About TLGTQ (Healthcare)
What does the AI Score mean for TLGTQ?
TLGTQ holds an AI Score of 40/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Teligent, Inc. is a specialty generic pharmaceutical company focusing on developing, manufacturing, and marketing generic topical and injectable products. The company filed for Chapter 11 …
What does Teligent, Inc. do?
Teligent, Inc. is a specialty generic pharmaceutical company that develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers a range of products in various dosage forms, including topical, injectable, complex, and ophthalmic. Teligent also engages in contract manufacturing and development, providing services to other pharmaceutical companies.
What do analysts say about TLGTQ stock?
As of March 16, 2026, there is limited analyst coverage on TLGTQ due to its OTC listing and bankruptcy status. Key valuation metrics, such as price-to-earnings ratio, are not meaningful given the company's negative profitability. The primary consideration for investors is the potential for successful reorganization and restructuring, which could improve the company's financial outlook. However, the stock remains highly speculative, and investors should carefully consider the risks involved.
What are the main risks for TLGTQ?
The main risks for TLGTQ include the uncertainty surrounding the Chapter 11 bankruptcy proceedings, the potential for liquidation, and the limited financial disclosure due to its OTC Other listing. The company also faces intense competition in the generic drug market, pricing pressures, and regulatory challenges.
What are the key factors to evaluate for TLGTQ?
Teligent, Inc. (TLGTQ) holds an AI score of 40/100 (low). presents a high-risk investment profile due to its Chapter 11 bankruptcy filing in October 2021. Not financial advice.
How frequently does TLGTQ data refresh on this page?
TLGTQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TLGTQ's recent stock price performance?
Teligent, Inc. (TLGTQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in topical and injectable generic drugs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TLGTQ overvalued or undervalued right now?
Teligent, Inc. (TLGTQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TLGTQ before investing?
Before investing in Teligent, Inc. (TLGTQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's bankruptcy status and OTC listing.
- AI analysis is pending and may provide additional insights.